Hemostasis Today
NewsFeed
Headlines Hematology Health Medicine VTE ASH Plasma Donation
February, 2026
February 2026
M T W T F S S
 1
2345678
9101112131415
16171819202122
232425262728  
Disaggro (Zalunfiban) for Pre-hospital Treatment of STEMI: Phase 3 Results to Be Presented at AHA 2025
Dirk Sibbing/LinkedIn
Oct 12, 2025, 01:27

Disaggro (Zalunfiban) for Pre-hospital Treatment of STEMI: Phase 3 Results to Be Presented at AHA 2025

CeleCor Therapeutics reposted from Dirk Sibbing on LinkedIn:

”Excited to see the news about our Phase 3 CeleBrate trial of Disaggro™ (zalunfiban) being picked up – appreciate the share Dirk Sibbing.

The full study results will be presented as part of the Late-Breaking Science Sessions at the American Heart Association Scientific Sessions (AHA 2025) in New Orleans on November 10, 2025.

Stay tuned!”

Quoting Dirk Sibbing‘s post:

”A new drug on the horizon for pre-hospital treatment of STEMI patients

Subcutaneous GPIIb/IIIa – Dissaggpro
Rapid onset and fast offset of antiplatelet action

Phase 3 Study (CeleBrate) of Novel Anti-Platelet Drug for Heart Attack Reports Positive Topline Results as announced by CeleCor Therapeutics

This, for sure, will bring new aspects into the discussions on pretreatment (antiplatelet) for STEMI patients…

Still we are loosing too many patients pre-hospital and before we see them in the cath lab…

Results will be presented as LBCT at AHA 2025 in New Orleans”

Read the full article here.

Disaggro (Zalunfiban) for Pre-hospital Treatment of STEMI: Phase 3 Results to Be Presented at AHA 2025

Stay updated on the emerging with Hemostasis Today.

AHA 2025 Anti-Platelet Drug CeleBrate CeleCor Therapeutics Dirk Sibbing Disaggro Health Hematology Hemostasis Hemostasis Today Medicine STEMI thrombosis Zalunfiban
NewsFeed